速尿联合多沙唑嗪治疗BPH/LUTS患者夜尿增多的研究

Frusemide plus doxazosin therapy for nocturia in patients with BPH/LUTS

目的:探讨速尿联合多沙唑嗪治疗BPH/LUTS患者夜尿增多的疗效及安全性。方法:将64例BPH/LUTS夜尿增多患者随机均分为两组,一组患者给予多沙唑嗪(4 mg/d),另一组患者给予速尿(睡前6 h40 mg)联合多沙唑嗪,两组患者分别治疗4周后,记录并分析治疗前后患者的尿量、IPSS评分、QOL评分、血电解质和血浆渗透压变化情况。结果:速尿联合多沙唑嗪组与单用多沙唑嗪组比较,夜尿次数明显减少(P<0.01),白天尿量增加(P<0.01),夜间尿量减少(P<0.01),总尿量无明显改变(P>0.05),IPSS评分下降(P<0.05),QOL评分明显下降(P<0.01),血钠、钾、氯、渗透压无明显变化(P>0.05)。结论:速尿联合多沙唑嗪治疗BPH/LUTS患者夜尿增多的疗效明显,4周的治疗是安全的。

Objective：To determine the efficacy and safety of a diuretic agent,frusemide,combined with doxazosin in the treatment of nocturia in patients with benign prostate hyperplasia / lower urinary tract symptoms（BPH/LUTS）.Methods：Sixty-four BPH/LUTS patients with nocturia were equally randomized into two groups,one treated with doxazosin（4 mg/d）,and the other with frusemide（40 mg/d） and doxazosin（4 mg/d）,given 6 h before sleep,both for 4 weeks.Urine volume,IPSS,QOL,serum electrolytes,plasma osmolality were recorded and compared between the two groups before and after the treatment.Results：Compared with the doxazosin group,the frusemide plus doxazosin group showed significantly reduced nocturia frequency（P 0.01）,increased daytime urine output（P 0.01）,decreased nocturia urine output（P 0.01）,unchanged total urine output（P 0.05）,improved IPSS and QOL（P 0.05,P 0.01）,but with no remarkable differences in the levels of serum sodium,potassium,chlorine,and osmotic pressure（P 0.05）.Conclusion：Four-week treatment with frusemide plus doxazosin was safe and effective for nocturia in patients with BPH/LUTS.